Several biotech and pharmaceutical companies are actively developing CAR-T (Chimeric Antigen Receptor T-cell) therapies. Some of the key players in the CAR-T field include:
- Novartis: Novartis is a leading pharmaceutical company that has developed one of the first FDA-approved CAR-T therapies, called Kymriah, for the treatment of pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Gilead Sciences: Gilead Sciences acquired Kite Pharma in 2017, a company that was a pioneer in the CAR-T field. Gilead is now developing a pipeline of CAR-T therapies for the treatment of cancer, including solid tumors.
- Juno Therapeutics (a subsidiary of Celgene, now part of Bristol-Myers Squibb): Juno Therapeutics is a biotech company that has developed a platform for engineering CAR-T cells, and has several CAR-T therapies in development for the treatment of cancer.
- Bluebird Bio: Bluebird Bio is a biotech company that is developing a pipeline of CAR-T therapies for the treatment of cancer and genetic diseases.
- Bellicum Pharmaceuticals: Bellicum Pharmaceuticals is a biotech company that is developing a platform for controlling the behavior of CAR-T cells, with the goal of improving their safety and efficacy.
These are some of the key players in the CAR-T field, but there are also many other biotech and pharmaceutical companies that are developing CAR-T therapies and related technologies. The CAR-T field is rapidly evolving, and new players are emerging all the time.
-poster-00001.jpg)
